Diamyd Medical executes a 2:1 division of shares (a split)
Diamyd Medical announces today that the company executes a 2:1 division of
shares (i.e. a split), meaning that each share is divided into two shares of the
same class.
At Diamyd´s Annual General Meeting on December 11, 2009, it was decided to
perform a division of shares in the ratio 2:1. Authorized by the Annual General
Meeting, the Board has determined the dates for the execution of the division as
follows.
Record day for the division is Thursday January 28, 2010. The last day of
trading in the Diamyd share before the division is Monday January 25, 2010. The
first day of trading with divided shares is Tuesday January 26.
The division of shares is done automatically through Euroclear and shareholders
do not need to take any measures. As a result of the division, the number of
shares will double but the share capital will remain unchanged. After the
division there will be 28,660,988 shares, consisting of 1,437,876 Series A
shares and 27,223,112 Series B shares.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Phone: +46 8 661 0026
For pictures and press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
andreas.ericsson@diamyd.com
Phone: +46 8 661 0026
Diamyd Medical is a Swedish diabetes company focusing on the development of
pharmaceuticals for the treatment of autoimmune diabetes and its complications.
The company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes. Phase III trials for this drug are in progress in both Europe and the
US. In addition, the company has initiated clinical studies in the US in the
area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS).
The company has also out-licensed the use of GAD for the treatment of
Parkinson's disease. The company currently has three clinical-phase products.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq
OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)
administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).
Further information is available on the company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.
Diamyd Medical AB (publ.)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46
(0)8 661 63 68
E-mail: info@diamyd.com. VAT no: SE556530-142001.
